Immunovant’s (IMVT) Overweight Rating Reaffirmed at Cantor Fitzgerald
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Benzinga reports. Several other equities analysts have also issued reports on the company. HC Wainwright restated a “buy” rating and set a $51.00 price target […]
More Stories
Morgan Stanley Lowers Marsh & McLennan Companies (NYSE:MMC) Price Target to $220.00
Marsh & McLennan Companies (NYSE:MMC – Free Report) had its target price lowered by Morgan Stanley from $225.00 to $220.00...
Redwire (NYSE:RDW) Coverage Initiated by Analysts at Bank of America
Bank of America assumed coverage on shares of Redwire (NYSE:RDW – Free Report) in a research note published on Monday...
Morgan Stanley Raises Primerica (NYSE:PRI) Price Target to $308.00
Primerica (NYSE:PRI – Free Report) had its price objective boosted by Morgan Stanley from $292.00 to $308.00 in a research...
Comstock (NYSE:LODE) Downgraded to Neutral Rating by LADENBURG THALM/SH SH
LADENBURG THALM/SH SH downgraded shares of Comstock (NYSE:LODE – Free Report) from a buy rating to a neutral rating in...
Jackson Financial (NYSE:JXN) Price Target Raised to $97.00
Jackson Financial (NYSE:JXN – Free Report) had its target price hoisted by Morgan Stanley from $92.00 to $97.00 in a...
Morgan Stanley Issues Pessimistic Forecast for MetLife (NYSE:MET) Stock Price
MetLife (NYSE:MET – Free Report) had its target price cut by Morgan Stanley from $98.00 to $94.00 in a research...